BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia - ALL08
Data

BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia - ALL08

Health Data Australia Contributor Records
Fleming, Shaun ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/XSAQ-2G82&rft.title=BLAM- A phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia - ALL08&rft.identifier=http://doi.org/10.58109/XSAQ-2G82&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=- ALL8 is a phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia. - The overall number of participants planned was 30 patients with newly diagnosed B-precursor Acute Lymphoblastic Leukaemia excluding Ph+ve. - Overall, the trial recruited 30 out of 30 patients. - The study included 22 male and 11 female patients, 40-65 years of age. - This study analysis aimed at identifying the factors involved in ALL in older adults along with factors correlating with response to combination immunotherapy and chemotherapy approaches will be performed. Data types - Data set included 30 patients. - Disease response collected as per NCCN 2015. - Quality of life (FACT-Leu v4) was collected. - Follow up data collected every 3months. - ECOS performance status was assessed for all 30 patients throughout the study until follow up. - 1 interim analysis was conducted on 31-July-2021. The analysis was performed when the first 10 patients registered on the study have been followed for at least 2 years or have experienced an event before being on study for 2 years. - Primary end point analysis is underway which is event-free status at 2 years from registration. -Cancer Australia demographic data Year of birth Aboriginal or Torres Strait Islander status (or Ethnicity)&rft.creator=Fleming, Shaun &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2024&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000084381&rft_subject=Chemotherapy&rft.type=dataset&rft.language=English Access the data

Full description

- ALL8 is a phase IIb study of Blinatumomab + Cytarabine (AraC) and Methotrexate in adult B-precursor Acute Lymphoblastic Leukaemia. - The overall number of participants planned was 30 patients with newly diagnosed B-precursor Acute Lymphoblastic Leukaemia excluding Ph+ve. - Overall, the trial recruited 30 out of 30 patients. - The study included 22 male and 11 female patients, 40-65 years of age. - This study analysis aimed at identifying the factors involved in ALL in older adults along with factors correlating with response to combination immunotherapy and chemotherapy approaches will be performed. Data types - Data set included 30 patients. - Disease response collected as per NCCN 2015. - Quality of life (FACT-Leu v4) was collected. - Follow up data collected every 3months. - ECOS performance status was assessed for all 30 patients throughout the study until follow up. - 1 interim analysis was conducted on 31-July-2021. The analysis was performed when the first 10 patients registered on the study have been followed for at least 2 years or have experienced an event before being on study for 2 years. - Primary end point analysis is underway which is event-free status at 2 years from registration. -Cancer Australia demographic data Year of birth Aboriginal or Torres Strait Islander status (or Ethnicity)

Notes

HeSANDA 1.0.1

Issued: 2024

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y327

Identifiers